Natco Kabanat 60mg Injection

Get a Price/Quote

MOQ : 10 Pieces

Natco Kabanat 60mg Injection Specification

Salt Composition
Cabazitaxel 60mg

Origin of Medicine
India

Dosage Form
Liquid Injection

Brand Name
Kabanat

Pacakaging (Quantity Per Box)
1 vial per box

Indication
Treatment of metastatic castration-resistant prostate cancer

Life Span
Refer expiry date on pack

Packaging Type
Vial

Drug Type
Prescription only medicine

Ingredients
Cabazitaxel

Physical Form
Injection

Function

Recommended For
Adults with metastatic prostate cancer

Dosage
As directed by oncologist

Dosage Guidelines
Administered intravenously by healthcare professional

Suitable For
Men

Quantity
1 Vial

Storage Instructions
Store below 25C, protect from light

Country of Registration
India

Route of Administration
Intravenous (IV)

Marketed By
Natco Pharma Ltd.

Side Effects
May cause neutropenia, anemia, diarrhea, fatigue

Warning
For hospital use only, cytotoxic agent

Volume
60mg/1.5ml

International Availability
Available in Canada, European Union, UK, USA, Australia

Prescription Requirement
Yes

Therapeutic Class
Antineoplastic agent

Natco Kabanat 60mg Injection About

Unlock an extraordinary treatment option with the superlative Natco Kabanat 60mg Injection-an exclusive, laureate solution for men battling metastatic castration-resistant prostate cancer. Featuring limited stock, this hot deal is available globally in Canada, the European Union, UK, USA, and Australia. Formulated by Natco Pharma Ltd., each 60mg/1.5ml vial is administered intravenously by healthcare professionals within hospital settings only. Store below 25C and protect from light. A cytotoxic, prescription-only medication, Kabanat ensures top-tier efficacy in advanced chemotherapy care. Act swiftly-this elite medicine is in limited supply!

Targeted Application and Usage of Natco Kabanat 60mg Injection

Natco Kabanat 60mg Injection is specifically indicated for adults with metastatic castration-resistant prostate cancer, marking it as a specialty therapeutic for advanced stages. The general use rests within the hospital, administered intravenously by trained oncologists. Its application is strictly under prescription, designed for male patients requiring intensive oncology intervention. This cytotoxic injection demands careful handling and adherence to clinical guidelines, ensuring optimal efficacy and patient safety during usage in comprehensive cancer treatment.

Global Export Network and Certifications of Natco Kabanat 60mg Injection

Natco Kabanat 60mg Injection enjoys robust supply to key international export markets including Canada, the European Union, UK, USA, and Australia. With Express Shipping from India through major FOB ports, this product is delivered reliably to global healthcare providers. Natco Pharma Ltd. upholds stringent certifications, ensuring regulatory compliance and quality assurance across borders. Trust in Natco's commitment for timely supply of this acclaimed anti-cancer therapy to hospitals worldwide.

FAQ's of Natco Kabanat 60mg Injection:

Q: How should Natco Kabanat 60mg Injection be administered?

A: This injection must be administered intravenously by a qualified healthcare professional, exclusively in a hospital or clinical setting as per the oncologist's guidance.

Q: What is the main therapeutic use of Kabanat 60mg Injection?

A: Kabanat 60mg Injection is primarily used in the treatment of metastatic castration-resistant prostate cancer in adult men.

Q: Where can Natco Kabanat 60mg Injection be exported or supplied?

A: This product is available for supply and export in Canada, the European Union, UK, USA, and Australia, with distribution networks from India's major FOB ports.

Q: What are the key side effects associated with Kabanat 60mg Injection?

A: Primary side effects may include neutropenia, anemia, diarrhea, and fatigue. Patients are closely monitored by medical professionals during the treatment.

Q: When is it recommended to use Natco Kabanat 60mg Injection?

A: This injection is recommended for adult males diagnosed with metastatic, castration-resistant prostate cancer, following an oncologist's assessment.